Vor Biopharma Inc. - 8-K Filing
Vor Biopharma enters amended license agreement with RemeGen to add RC298 dual-target fusion protein to existing portfolio. (Items: 1.01 Entry into a Material Definitive Agreement, 3.02 Unregistered Sales of Equity Securities, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $VOR